The BD Veritor™ Plus System offers simple operation, an efficient workflow, and fast, traceable results, which may help improve the patient experience.
| PPA† | NPA‡ | Results in |
Influenza A CLIA-waived | 83.6% (76.1%, 89.1%) | 97.5% (95.7%, 98.5%) |
10 minutes
|
Influenza B CLIA-waived | 81.3% (71.1%, 88.5%) | 98.2% (95.7%, 99.3%) | 10 minutes |
Flu A+B results in 10 minutes
†positive percent agreement
‡negative percent agreement
Ordering information | Cat no. | Qty |
BD Veritor™ Plus System Flu A+B CLIA-waived kit | 256045 | 30 tests |
BD Veritor™ Plus System Flu A+B moderately complex kit | 256041 | 30 tests |
Adapts easily to your workflow by offering 2 operational modes
The BD Veritor™ Plus System provides an easy sample-collection process that can be incorporated across a variety of clinical settings.
See how BD supports you with tools, education, and training—enabling a streamlined point-of-care experience for those you serve, and confidence in your results.
The BD Veritor™ Plus System enhances point-of-care testing for COVID-19, Flu A+B, COVID-19 & Flu A+B,* RSV and Group A Strep, providing rapid diagnostic testing in a convenient, portable instrument.
1. BD Veritor™ Plus System for Rapid Detection of Flu A+B. Package insert. 8087667 Becton, Dickinson and Company.
BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663
*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
bd.com